Abstract CT156: Changes in circulating tumor assoc
Post# of 154641
(Total Views: 615)
Posted On: 06/20/2022 9:10:54 PM
Abstract CT156: Changes in circulating tumor associated cells predicts progression free and overall survival in metastatic TNBC patients after induction of the anti-CCR5 drug Leronlimab
https://aacrjournals.org/cancerres/article/82...156/703662
What is this abstract saying?
Dated June 15, 2022. Only 5 days old.
mTNBC is a difficult cancer to treat with poor clinical outcomes.
Leronlimab (PRO140), a humanized IgG4κ monoclonal antibody, is a competitive inhibitor of CCR5, with 3 active clinical trials ongoing in TNBC patients.
Key word here is ACTIVE. ACTIVE, not recruiting . Patients remain alive. In cancer trials, patients continue to be treated until they opt out or die. Then Overall Survivability is calculated.
The Abstract evaluated the predictive value of TACs,
Regardless that there were 5 patients out of 28, (18%) whose CTCs had increased, there were 23 patients of the 28, (82%), whose CTCs had decreased by the end of the 1st treatment cycle, (28 days).
p = 0.0296 is 1 in 34 chance that (a drop in CTC #s at end of 1st treatment cycle, (28 days), indicated better Progression Free Survival), could have just randomly occurred in the placebo group.
p = 0.0019 is a 1 in 53 chance that (a drop in CTC #s at end of 1st treatment cycle, (28 days), indicated better Overall Survivability), could have just randomly occurred in the placebo group.
In 100% of the patients, if an increase was appreciated in either CAMLs or CTCs by the end of 1st Treatment Cycle, (28 days), is strongly predicted for worse Progression Free Survival and worse Overall Survivability.
p = 0.0354 is a 1 in 28 chance that (an increase in either CAMLs or CTCs by the end of the 1st Treatment Cycle, (28 days), indicated worse Progression Free Survival), could have just randomly occurred in the placebo group.
p = 0.0004 is a 1 in 250 chance that (an increase in either CAMLs or CTCs by the end of the 1st Treatment Cycle, (28 days), indicated worse Overall Survivability), could have just randomly occurred in the placebo group.
//
What all of this is CLEARLY pointing to is the fact that CytoDyn now has verified a testing method to assess within the 1st Treatment Cycle, (28 days), whether or not the current method of treatment would be successful in improving the patient's progression free survival and overall survivability or if the current method of treatment would result in a worsened progression free survival and a worsened overall survivability.
If you have a decrease in CTCs in the 1st 28 days, the patient would benefit from current treatment.
If you have an increase in either CTCs or CAMLs, the patient would not benefit from current treatment.
THIS TEST MAY BE USED TO DETERMINE AT EXACTLY WHICH POINT TO STOP TREATMENT. AS SOON AS EITHER CTCs OR CAMLs INCREASE AS COMPARED TO PRIOR MONTH, TREATMENT MAY BE STOPPED AS THERE WILL NO LONGER BE ANY BENEFIT TO CONTINUING THERAPY.
This test will be able to assess when the Cancer Returns. When the Cancer comes out of Remission. That means that Leronlimab should be MAINTAINED until the measured CTC is greater than it was the month prior. It should be given monthly until the CTC count is greater than the month prior. By no means should Leronlimab be discontinued at some predefined point when the current CTC count is less than the prior month.
https://aacrjournals.org/cancerres/article/82...156/703662
What is this abstract saying?
Dated June 15, 2022. Only 5 days old.
mTNBC is a difficult cancer to treat with poor clinical outcomes.
Leronlimab (PRO140), a humanized IgG4κ monoclonal antibody, is a competitive inhibitor of CCR5, with 3 active clinical trials ongoing in TNBC patients.
Key word here is ACTIVE. ACTIVE, not recruiting . Patients remain alive. In cancer trials, patients continue to be treated until they opt out or die. Then Overall Survivability is calculated.
The Abstract evaluated the predictive value of TACs,
Quote:
Evaluating CTC change was limited, as only 5 patients had any CTC increase, although the absence or drop of CTCs at T1 was significant for better PFS (HR=13.7 CI 95% 2.0-93.8, p=0.0296) and better OS (HR=397.7 CI 95% 19.3-100+, p=0.0019). By comparison, CAMLs or CTCs were evaluable in 100% of patients, with an increases of either population at T1 also significantly predicting for worse PFS (HR=5.8 CI 95% 1.4-23.6, p=0.0354) and worse OS (HR=36.0 CI 95% 6.2-207.6, p=0.0004).
Regardless that there were 5 patients out of 28, (18%) whose CTCs had increased, there were 23 patients of the 28, (82%), whose CTCs had decreased by the end of the 1st treatment cycle, (28 days).
p = 0.0296 is 1 in 34 chance that (a drop in CTC #s at end of 1st treatment cycle, (28 days), indicated better Progression Free Survival), could have just randomly occurred in the placebo group.
p = 0.0019 is a 1 in 53 chance that (a drop in CTC #s at end of 1st treatment cycle, (28 days), indicated better Overall Survivability), could have just randomly occurred in the placebo group.
In 100% of the patients, if an increase was appreciated in either CAMLs or CTCs by the end of 1st Treatment Cycle, (28 days), is strongly predicted for worse Progression Free Survival and worse Overall Survivability.
p = 0.0354 is a 1 in 28 chance that (an increase in either CAMLs or CTCs by the end of the 1st Treatment Cycle, (28 days), indicated worse Progression Free Survival), could have just randomly occurred in the placebo group.
p = 0.0004 is a 1 in 250 chance that (an increase in either CAMLs or CTCs by the end of the 1st Treatment Cycle, (28 days), indicated worse Overall Survivability), could have just randomly occurred in the placebo group.
//
What all of this is CLEARLY pointing to is the fact that CytoDyn now has verified a testing method to assess within the 1st Treatment Cycle, (28 days), whether or not the current method of treatment would be successful in improving the patient's progression free survival and overall survivability or if the current method of treatment would result in a worsened progression free survival and a worsened overall survivability.
If you have a decrease in CTCs in the 1st 28 days, the patient would benefit from current treatment.
If you have an increase in either CTCs or CAMLs, the patient would not benefit from current treatment.
THIS TEST MAY BE USED TO DETERMINE AT EXACTLY WHICH POINT TO STOP TREATMENT. AS SOON AS EITHER CTCs OR CAMLs INCREASE AS COMPARED TO PRIOR MONTH, TREATMENT MAY BE STOPPED AS THERE WILL NO LONGER BE ANY BENEFIT TO CONTINUING THERAPY.
This test will be able to assess when the Cancer Returns. When the Cancer comes out of Remission. That means that Leronlimab should be MAINTAINED until the measured CTC is greater than it was the month prior. It should be given monthly until the CTC count is greater than the month prior. By no means should Leronlimab be discontinued at some predefined point when the current CTC count is less than the prior month.
(13)
(0)